MedTrace Logo

Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers

NCT00473720 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2013-01-23

No results posted yet for this study

Summary

This is a phase I dose escalating study of oral satraplatin in combination with Abraxane administered weekly for three out of every four weeks in patients with advanced solid cancers.

Conditions

Interventions

DRUG

Satraplatin

Dose escalation of 40, 60 and 80 mg/m²/day on days 1-5

DRUG

Abraxane

Dose escalation of 80 and 100 mg/mm²/day on days 1,8,15,22 every 28 days

Sponsors & Collaborators

  • Agennix

    collaborator INDUSTRY

  • Yale University

    lead OTHER

Principal Investigators

  • Hari Deshpande, M.D. · Yale University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00473720 on ClinicalTrials.gov